Management of malignant pleural effusions

Department of Pulmonary Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
Advances in Therapy (Impact Factor: 2.44). 06/2010; 27(6):334-47. DOI: 10.1007/S12325-010-0031-8
Source: PubMed

ABSTRACT Malignant pleural effusions are a common clinical problem in patients with primary thoracic malignancy and metastatic malignancy to the thorax. Symptoms can be debilitating and can impair tolerance of anticancer therapy. This article presents a comprehensive review of pharmaceutical and nonpharmaceutical approaches to the management of malignant pleural effusion, and a novel algorithm for management based on patients' performance status.

Download full-text


Available from: M.P. Kennedy, Aug 20, 2014
  • Source
    • "talc particles (mean size 24.4 microns) are safer and do not provoke acute respiratory distress syndrome (ARDS), the principal complication of talc pleurodesis [7] [9]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to examine the role of TLR2 molecule in pleural space during thoracoscopic talc pleurodesis period in patients with malignant pleural effusion. We analyzed TLR2 molecule in soluble form as well as on membrane of granulocytes in pleural fluid. Pleural fluid examination was done at three intervals during pleurodesis procedure: 1st-before the thoracoscopic procedure, 2nd-2 hours after the terminating thoracoscopic procedure with talc insufflation, 3rd-24 hours after the thoracoscopic procedure. We reported significant increase of soluble TLR2 molecule in pleural fluid effusion during talc pleurodesis from preoperative value. This increase was approximately 8-fold in the interval of 24 hours. The changes on granulocyte population were quite different. The mean fluorescent intensity of membrane TLR2 molecule examined by flow cytometry on granulocyte population significantly decreased after talc exposure with comparison to prethoracoscopic density. To estimate the prognostic value of TLR2 expression in pleural fluid patients were retrospectively classified into either prognostically favourable or unfavourable groups. Our results proved that patients with favourable prognosis had more than 3-fold higher soluble TLR2 level in pleural fluid early, 2 hours after talc pleurodesis intervention.
    Clinical and Developmental Immunology 12/2012; 2012:158287. DOI:10.1155/2012/158287 · 2.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interventional Radiology (IR) is occupying an increasingly prominent role in the care of patients with cancer, with involvement from initial diagnosis, right through to minimally invasive treatment of the malignancy and its complications. Adequate diagnostic samples can be obtained under image guidance by percutaneous biopsy and needle aspiration in an accurate and minimally invasive manner. IR techniques may be used to place central venous access devices with well-established safety and efficacy. Therapeutic applications of IR in the oncology patient include local tumour treatments such as transarterial chemo-embolisation and radiofrequency ablation, as well as management of complications of malignancy such as pain, organ obstruction, and venous thrombosis.
    03/2011; 2011:160867. DOI:10.1155/2011/160867
  • [Show abstract] [Hide abstract]
    ABSTRACT: Malignant pleural effusions (MPEs) are one of the most common problems faced by clinicians and, since there is no optimum treatment available, they deserve efforts aimed to improve their management. We have reviewed the most recent articles regarding treatment of MPE, with special emphasis on pleurodesis and indwelling pleural catheter placement. Although iodopovidone, silver nitrate and doxycycline are useful, talc continues to be the most effective agent available for pleurodesis. Use of calibrated talc with large particle size is now firmly established, in order to prevent complications. Indwelling pleural catheters are gaining general acceptance, and they are currently a valid option for patients with lung entrapment or those who have a previous failed pleurodesis. Advances in translational medicine related to this topic are also described. The above results may contribute to improve significantly management of patients with malignant pleural effusions, especially those with advanced disease who are not suitable for pleurodesis procedures.
    Current opinion in pulmonary medicine 07/2011; 17(4):269-73. DOI:10.1097/MCP.0b013e3283474015 · 2.96 Impact Factor
Show more